NCT04926909

Study on Serum Cystatin C and PET-DAT in Patients With Parkinson's Disease

The Relationship Between Serum Cystatin C and PET-DAT Study in Patients With Parkinson's Disease

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 121 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To investigate the relationship between serum cystatin C and dopamine receptor(DAT) loss in patients with parkinson's disease(PD)

Detailed description

Number of people suffered from Parkinson disease (PD) is increasing every year. PET imaging of dopamine transport receptors（DAT） serves as the gold standard for the diagnosis and monitoring of PD development. However, due to high costs and radiation reasons, it is not suitable for long-term follow-up. Serum cystatin C can be easily obtained and cheap as an indicator. In recent years, studies have gradually found that it is related to the progression of H\&Y staging of Parkinson's disease. To this extent, we want to further explore whether it can reflect the loss of DAT in the brain. Explore whether it can partially replace the role of DAT imaging for future clinical evaluation.

Conditions

• Parkinson's Disease

Timeline

• Start date: 2020-07-01
• Primary completion: 2021-07-01
• Completion: 2021-08-01
• First posted: 2021-06-15
• Last updated: 2021-06-15

Locations

1 site across 1 country: China